• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Wong Hing C bought $3,741 worth of shares (1,800 units at $2.08), increasing direct ownership by 0.01% to 15,314,868 units

    9/18/23 4:36:51 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCWB alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Wong Hing C

    (Last) (First) (Middle)
    C/O HCW BIOLOGICS INC
    2929 N. COMMERCE PARKWAY

    (Street)
    MIRAMAR FL 33025

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    HCW Biologics Inc. [ HCWB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    09/14/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/14/2023 P 1,800 A $2.0782(1) 15,314,868 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The range of prices for the shares of Common Stock is from $2.0536 to $2.1109. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.
    Remarks:
    /s/ Nicole Valdivieso, as Attorney-in-Fact for Hing C. Wong 09/18/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HCWB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HCWB

    DatePrice TargetRatingAnalyst
    11/19/2021$10.00Buy
    EF Hutton
    More analyst ratings

    $HCWB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Wong Hing C bought $60,002 worth of shares (8,054 units at $7.45), increasing direct ownership by 2% to 501,911 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:35 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Winer Gary M bought $9,998 worth of shares (1,342 units at $7.45), increasing direct ownership by 49% to 4,075 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:07 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Garrett Scott T bought $100,001 worth of shares (13,423 units at $7.45), increasing direct ownership by 111% to 25,505 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:34:34 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EF Hutton initiated coverage on HCW Biologics with a new price target

      EF Hutton initiated coverage of HCW Biologics with a rating of Buy and set a new price target of $10.00

      11/19/21 8:39:08 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    SEC Filings

    See more
    • HCW Biologics Inc. filed SEC Form 8-K: Other Events

      8-K - HCW Biologics Inc. (0001828673) (Filer)

      7/1/25 8:30:29 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - HCW Biologics Inc. (0001828673) (Filer)

      6/26/25 8:00:29 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - HCW Biologics Inc. (0001828673) (Filer)

      6/23/25 4:40:38 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Wong Hing C bought $60,002 worth of shares (8,054 units at $7.45), increasing direct ownership by 2% to 501,911 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:35 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Winer Gary M bought $9,998 worth of shares (1,342 units at $7.45), increasing direct ownership by 49% to 4,075 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:07 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Garrett Scott T bought $100,001 worth of shares (13,423 units at $7.45), increasing direct ownership by 111% to 25,505 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:34:34 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

      Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated Presentation at the Phoenix Best Science Series by HonorHealth Research Instituteon June 27, 2025 in Scottsdale, Arizona MIRAMAR, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today that its scientists have success

      6/27/25 7:45:56 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

      MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). On June 24, 2025, HCWB received formal notice from Nasdaq confirming that the Company has satisfied

      6/26/25 7:55:49 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

      MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that WY Biotech has completed its due diligence related to HCWB's technology transfer report, including the characterization of the cell line, delivered on May 13, 2025. In addition, WY Biotech confirmed its commitmen

      6/4/25 8:20:19 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Leadership Updates

    Live Leadership Updates

    See more
    • HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

      MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.  Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "These are exciting times at HCW Biologics. We achieved two major clinical milestones, with the completion of the Phase 1 clinical study to evaluate HCW9218 in solid tumors and the Phase 1b stu

      4/1/24 4:10:32 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by HCW Biologics Inc.

      SC 13D/A - HCW Biologics Inc. (0001828673) (Subject)

      11/22/24 4:53:35 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Financials

    Live finance-specific insights

    See more
    • HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

      MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2022. "We have achieved several milestones in the first half of 2022, and some important pieces of our strategic plan have fallen into place. First, we are now a clinical-stage company, with the entry of our lead product candidate, HCW9218, into the clinic in a

      8/12/22 7:00:00 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

      MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022. "We continue to successfully execute our clinical development strategy which is based on our unique approach toward inflammaging," stated Hing C. Wong, Founder and CEO of HCW Biologics Inc. "HCW Biologics is developing immunotherapeutics that do not treat a single indica

      5/13/22 7:15:00 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care